Angiogenesis and inflammation in ductal carcinoma in situ of the breast

Journal of Pathology

Volumn 181, Issue 2, 1997, Pages 200-206

  Lee, Andrew H S ^a,b   Happerfield, Lisa C ^a   Borrow, Lynda G ^a   Millis, Rosemary R ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Breast; Carcinoma; Inflammation; Intraductal; Neovascularization; Non infiltrating

Indexed keywords

CD20 ANTIGEN; CD3 ANTIGEN; CD45 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; CYTOKINE; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ARTICLE; B LYMPHOCYTE; BREAST CARCINOMA; BREAST CARCINOMA IN SITU; CARCINOMA IN SITU; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; INFLAMMATION; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0031018590     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199702)181:2<200::AID-PATH726>3.0.CO;2-K     Document Type: Article

References (34)

1. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
2. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84: 1875-1887.
3. Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/ endothelial cell adhesion molecule antibodies, as an indicator of node metastases and survival in breast cancer. Lancet 1992; 340: 1120-1124.
4. Rilke F, Colnaghi MI, Cascinelli N, et al. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 1991; 49: 44-49.
5. Alderson MR, Hamlin I, Staunton MD. The relative significance of prognostic factors in breast carcinoma. Br J Cancer 1971; 25: 646-656.
6. Roses DF, Bell DA, Flotte TJ, Taylor R, Ratech H, Dubin N. Pathologic predictors of recurrence in stace 1 (T1N0M0) breast cancer. Am J Clin Pathol 1982; 78: 817-820.
7. Parl FF, Dupont WD. A retrospective cohort study of histologic risk factors in breast cancer patients. Canter 1982; 50: 2410-2416.
8. Brem SS, Jensen HM, Gullino PM. Angiogenesis as a marker of preneoplastic lesions of the human breast. Cancer 1978; 41: 239-244.
9. Bosari S, Lee AKC, Delellis RA, Wiley BD, Heatley GJ, Silverman M. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992; 23: 755-761.
10. Van Hoef MEHM, Knox WF, Dhesi SS, Howell A, Schor AM. Assessment of tumour vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 1993; 8: 1341-1145.
11. Guidi AJ, Fischer L, Harris JR, Schnitt SJ. Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 1994; 86: 614-619.
12. Ramachandra S, Machin L, Ashley S, Monaghan P, Gusterson BA. Immunohistochemical distribution of c-erbB-2 in in situ breast carcinoma - a detailed morphological analysis. J Pathol 1990; 161: 7-14.
13. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994; 11: 167-180.
14. Lee AHS, Happerfield LC, Millis RR, Bobrou LG. Inflammatory infiltrates in invasive lobular and ductal carcinoma of the breast. Br J Cancer 1996; 74: 796-801.
15. Bhan AK, DesMarais CL. Immunohistologic characterisation of major histocompatibility antigens and inflammatory cellular infiltrate in human breast cancer. J Natl Cancer Inst 1983; 71: 507-516.
16. Gotllinger HG, Rieber P, Gokel JM, Lohe KJ, Riethmuller G. Infiltrating mononuclear cells in human breast carcinoma: predominance of T4 + monocytic cells in the tumor stroma. Int J Cancer 1985; 35: 199-205.
17. Zuk JA, Walker RA. Immunohistochemical analysis of HLA antigens and mononuclear infiltrates of benign and malignant breast. J Pathol 1987; 152: 275-285.
18. Lammie GA, Bubrow LG, Staunton MDM, Levison DA, Page G, Millis RR. Sclerosing lymphoeytic lobulitis of the breast - evidence for an autoimmune pathogenesis. Histopathology 1991; 19: 13-20.
19. Suhwartz IS, Strsuchen JA. Lymphoeytic mastopathy. An autoimmune disease of the breast? Am J Clin Pathol 1990; 93: 725-730.
20. Kabel PJ, Voorbij HAM, de Haan-Meulman M, Pals ST, Drexhage HA. High endothelial venules present in lymphoid cell accumulations in thyroids affected by autoimmune disease: a study in men and BB rats of functional activity and development. J Clin Endocrinol Metab 1989; 68: 744-751.
21. van Dinther-Janssen ACHM, Pals ST, Scheper R, Breedveld F, Meijer CJLM. Dendritic cells and high endothelial venules in the rheumatoid synovial membrane. J Rheumatol 1990; 17: 11-17.
22. Coyne JD, Baildam AD, Asbury D. Lymphoeytic mastopathy associated with ductal carcinoma in situ of the breast. Histopathology 1995; 26: 579-580.
23. Elston CW, Gresham GA, Rao GS, et al. The Cancer Research Campaign (King's/Cambridge) trial for early breast cancer: clinico-pathological aspects. Br J Cancer 1982; 45: 655-469.
24. Aaltomaa S, Lipponen P, Eskelinen M, et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 1992; 28A: 859-864.
25. Scholl SM, Pallud C, Beuvon F, et al. Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 1994; 86: 120-126.
26. Bose S, Lesser ML, Norton L, Rosen PP. Immunophenotype of intraductal carcinoma. Arch Pathol Lab Med 1996; 120: 81-85.
27. Yassin R, Heffelfinger S, Miller MA, Fenoglio-Preiser C. Angiogenesis of in situ ductal carcinoma and proliferative ductal lesions of breast. Am J Clin Pathol 1994; 102: 529 (Abstract).
28. Silverstein MJ, Waisman JR, Gamagami P, et al. Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer 1990; 66: 102-108.
29. van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer, N Engl J Med 1988; 319: 1239-1245.
30. Poller DN, Silverstein MJ, Galea M, et al. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification. Association between cellular proliferation and c-erbB-2 protein expression. Mod Pthol 1994; 7: 257-262.
31. Zafrani B, Leroyer A, Fourquet A, et al. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors. p53 and c-erb-B2 proteins, and proliferative activity. Semin Diagn Pathol 1994; 11: 208-214.
32. Bobrow LG, Happerfield LC, Gregory WM, Millis RR. Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers. J Pathol 1995; 176: 333-341.
33. De Potter CR, Schelfhout A-M, Verbeeck P, et al. Neu overexpression correlates with extent of disease in large cell ductal carcinoma in situ of the breast. Hum Pathol 1995; 26: 601-606.
34. Guidi AJ, Abu-Jawdeh G, Berse B, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995; 87: 1237-1245.